AU
UK
CA
NZ
IND
US
Last update at 2026-06-05T20:02:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Fri 13 Mar 26, 12:35 PMLife Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Tue 10 Mar 26, 02:21 PMPresenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
Wed 21 May 25, 11:00 AMPresenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream
Tue 20 May 25, 11:00 AMPresenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
Tue 25 Mar 25, 11:00 AMPresenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
Wed 19 Feb 25, 11:00 AMPresenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now
Wed 01 Nov 23, 11:00 AMPresenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now
Tue 31 Oct 23, 11:00 AMPresenting on the Emerging Growth Conference on September 6 and 7 Register Now
Tue 05 Sep 23, 11:00 AMPresenting on the Emerging Growth Conference on August 9 & 10 Register Now
Tue 08 Aug 23, 11:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -48.39500M | -52.60000M | -33.80900M | -38.52944M | -32.14606M |
| Minority interest | 0.94M | 0.00500M | - | - | - |
| Net income | -47.45400M | -60.25100M | -36.79100M | -38.53944M | -32.14606M |
| Selling general administrative | 17.87M | 17.10M | 14.39M | 13.50M | 12.28M |
| Selling and marketing expenses | 8.84M | 8.89M | 6.61M | 6.94M | 9.83M |
| Gross profit | 9.94M | 2.00M | 6.11M | 1.96M | 1.65M |
| Reconciled depreciation | 2.29M | 1.81M | 2.28M | 1.93M | 1.32M |
| Ebit | -34.41500M | -39.07400M | -21.30400M | -24.94811M | -21.39323M |
| Ebitda | -31.17300M | -39.66000M | -24.17700M | -22.93907M | -20.07423M |
| Depreciation and amortization | 3.24M | -0.58600M | -2.87300M | 2.01M | 1.32M |
| Non operating income net other | - | - | -1.67400M | -4.86008M | -0.22875M |
| Operating income | -34.41500M | -39.07400M | -21.30400M | -24.94811M | -30.82397M |
| Other operating expenses | 46.37M | 43.41M | 30.69M | 30.72M | 30.03M |
| Interest expense | 12.72M | 8.42M | 2.79M | 5.73M | 2.63M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.01000M | 0.00000M |
| Interest income | - | - | - | 4.72M | 2.30M |
| Net interest income | -12.72300M | -10.05500M | -8.13500M | -5.73065M | -2.62868M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | 4.00M | 5.21M |
| Other items | - | - | - | - | - |
| Income tax expense | -0.94100M | 7.65M | 2.98M | 0.01000M | -1.27554M |
| Total revenue | 11.96M | 4.33M | 9.38M | 5.78M | 4.42M |
| Total operating expenses | 44.35M | 41.08M | 27.41M | 26.91M | 27.26M |
| Cost of revenue | 2.02M | 2.33M | 3.28M | 3.82M | 2.77M |
| Total other income expense net | -13.98000M | -13.52600M | -12.50500M | -13.58132M | -3.90422M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -48.39500M | -52.60000M | -33.80900M | -38.53944M | -32.14606M |
| Net income applicable to common shares | - | -52.59500M | -38.64800M | -32.35263M | -32.14606M |
| Preferred stock and other adjustments | - | - | 4.71M | -6.18681M | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 50.76M | 47.45M | 53.27M | 42.84M | 36.41M |
| Intangible assets | 20.12M | 22.44M | 22.65M | 24.34M | 26.02M |
| Earning assets | - | - | - | - | - |
| Other current assets | 10.12M | 7.36M | 4.34M | 2.36M | 0.55M |
| Total liab | 45.87M | 48.81M | 41.41M | 25.64M | 25.74M |
| Total stockholder equity | 4.96M | -0.65700M | 11.61M | 17.20M | 10.67M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 3.80M | 8.16M | 0.00100M | 0.18M | 0.00349M |
| Common stock | 0.00700M | - | 0.00500M | 0.01M | 0.00546M |
| Capital stock | - | 0.00000M | 0.00500M | 0.01M | 1.72M |
| Retained earnings | -308.24800M | -266.94800M | -219.49400M | -166.89900M | -133.09022M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | - | 0.45M | 0.04M | 0.15M |
| Cash | 6.47M | 5.47M | 17.05M | 8.09M | 3.50M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 13.99M | 30.34M | 15.47M | 13.22M | 15.39M |
| Current deferred revenue | - | - | 7.12M | 4.49M | 2.92M |
| Net debt | 30.62M | 29.37M | 12.31M | 8.12M | 4.07M |
| Short term debt | 5.21M | 16.37M | 3.42M | 3.79M | 7.12M |
| Short long term debt | - | 15.88M | 3.18M | 3.79M | 6.78M |
| Short long term debt total | 37.09M | 34.84M | 29.36M | 16.21M | 7.57M |
| Other stockholder equity | 313.85M | 266.97M | 231.10M | 184.09M | 142.05M |
| Property plant equipment | - | - | 1.73M | 0.68M | 0.71M |
| Total current assets | 27.96M | 22.32M | 28.43M | 17.79M | 9.52M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | -11.04000M | -7.13500M | -7.16785M |
| Short term investments | - | - | - | - | - |
| Net receivables | 2.18M | 2.47M | 2.14M | 4.56M | 1.69M |
| Long term debt | - | 17.74M | 25.02M | 12.42M | 0.45M |
| Inventory | 9.19M | 7.02M | 4.90M | 2.78M | 2.13M |
| Accounts payable | 4.97M | 5.81M | 4.93M | 4.76M | 5.35M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.65200M | -0.68000M | - | -42.84300M | -0.22407M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.01M | 0.00546M |
| Preferred stock total equity | - | - | - | - | 1.71M |
| Retained earnings total equity | - | - | - | -166.89900M | -133.09022M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.01M | 0.99M | 0.45M | 0.04M | 0.15M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 22.80M | 25.13M | 24.83M | 25.05M | 26.89M |
| Capital lease obligations | - | 1.21M | 1.16M | 0.00000M | 0.34M |
| Long term debt total | - | - | - | 12.42M | 0.45M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1.67500M | -0.00600M | -0.00700M | 0.00000M | -0.00653M |
| Change to liabilities | - | 0.16M | -0.74300M | -1.12212M | 1.32M |
| Total cashflows from investing activities | - | -0.00600M | -0.00700M | -0.00700M | -0.00653M |
| Net borrowings | - | 8.11M | 12.06M | -0.10000M | 1.35M |
| Total cash from financing activities | 23.18M | 43.94M | 19.49M | 21.77M | 24.55M |
| Change to operating activities | - | 1.40M | 0.77M | -1.11651M | 2.99M |
| Net income | -49.07500M | -52.60000M | -33.80900M | -38.53944M | -32.14606M |
| Change in cash | -11.58200M | 8.96M | 4.21M | 1.32M | 1.81M |
| Begin period cash flow | 17.05M | 8.09M | 3.88M | 2.57M | 0.76M |
| End period cash flow | 5.47M | 17.05M | 8.09M | 3.88M | 2.57M |
| Total cash from operating activities | -33.10400M | -34.97000M | -15.27800M | -20.45681M | -22.73083M |
| Issuance of capital stock | 20.46M | 33.58M | 1.95M | 12.65M | 25.88M |
| Depreciation | 2.29M | 1.81M | 2.28M | 1.93M | 1.32M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | 0.03M | - | 12.24M |
| Change to inventory | -2.12400M | -2.11800M | -0.65300M | 1.21M | -1.26936M |
| Change to account receivables | -0.17000M | 2.82M | -2.84000M | -0.69603M | -0.52802M |
| Sale purchase of stock | - | - | 0.03M | 3.08M | -0.00003M |
| Other cashflows from financing activities | 2.82M | 12.28M | 18.63M | 20.29M | 22.36M |
| Change to netincome | - | 8.38M | 17.05M | 11.93M | 7.80M |
| Capital expenditures | 1.68M | 0.00600M | 0.00700M | 0.00700M | 0.00653M |
| Change receivables | - | - | -2.86600M | -0.70388M | -0.53276M |
| Cash flows other operating | - | - | 10.61M | -0.26873M | -0.42105M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 4.21M | 1.32M | 1.81M |
| Change in working capital | -4.42800M | 2.27M | -3.46700M | -0.66177M | -0.92510M |
| Stock based compensation | 3.32M | 3.97M | 2.82M | 2.99M | 2.02M |
| Other non cash items | 14.79M | 5.19M | 6.57M | 5.90M | 1.25M |
| Free cash flow | -34.77900M | -34.97600M | -15.28500M | -20.45681M | -22.73736M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| JAGX Jaguar Animal Health Inc |
-0.25 8.20% | 2.80 | 0.14 | - | 2.56 | 5.15 | 5.75 | -1.6955 |
| NVO Novo Nordisk A/S |
-0.79 1.81% | 42.96 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.6937 1.57% | 43.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.09 1.15% | 446.83 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.72 1.07% | 635.45 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
200 Pine Street, San Francisco, CA, United States, 94104
| Name | Title | Year Born |
|---|---|---|
| Ms. Lisa A. Conte | Founder, CEO, Pres & Director | 1959 |
| Mr. Jonathan S. Wolin CPA, J.D., M.B.A. | Chief of Staff, Chief Compliance Officer & Gen. Counsel | 1962 |
| Mr. Ian H. Wendt M.B.A. | Chief Commercial Officer | 1968 |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. | 1958 |
| Ms. Carol R. Lizak | Chief Financial Officer | 1964 |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer & Chair of Scientific Advisory Board | 1963 |
| Mr. Peter Hodge | Sr. Director of Investor Relations, Bus. Devel. & Special Events | NA |
| Dr. Karen J. Brunke Ph.D. | Exec. VP of Corp. & Bus. Devel. | 1952 |
| Mr. David Sesin | Chief Manufacturing Officer | NA |
| Dr. Michael K. Guy D.V.M., M.S., Ph.D. | VP of Preclinical & Nonclinical Studies | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...